A randomized placebo-controlled phase IIb trial of A3309, a bile acid transporter inhibitor, for chronic idiopathic constipation

American Journal of Gastroenterology

Volumn 106, Issue 10, 2011, Pages 1803-1812

  Chey, William D ^a   Camilleri, Michael ^b   Chang, Lin ^c   Rikner, Leif ^d   Graffner, Hans ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 ALPHA HYDROXY 4 CHOLESTEN 3 ONE; A 3309; BILE ACID; CHOLESTEROL; GASTROINTESTINAL AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BILE ACID SYNTHESIS; BLOATING; CHOLESTEROL BLOOD LEVEL; CHRONIC IDIOPATHIC CONSTIPATION; CONSTIPATION; CONTROLLED STUDY; DEFECATION HABIT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTESTINE FUNCTION; INTESTINE MOTILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ABDOMINAL PAIN; ADULT; AGED; CARRIER PROTEINS; CHRONIC DISEASE; CONSTIPATION; DEFECATION; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 80053912847     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.162     Document Type: Article

References (31)

1. Talley NJ. Functional gastrointestinal disorders as a public health problem . Neurogastroenterol Motil 2008; 20 (Suppl 1): 121-9. (Pubitemid 351514531)
2. Higgins PD, Johansen JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004; 99: 750-9. (Pubitemid 38612817)
3. Pare P, Ferrazzi S, Thompson WG, et al. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001; 96: 3130-7. (Pubitemid 33095352)
4. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007; 25: 599-608.
5. Hofmann AF, Poley J R. Cholestyramine treatment of diarrhea associated with ileal resection. N Engl J Med 1969; 281: 397-402.
6. Hofmann AF, Loening-Baucke V, Lavine JE, et al. Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. J Pediatr Gastroenterol Nutr 2008; 47: 598-606.
7. Abrahamsson H, Ostlund-Lindqvist AM, Nilsson R, et al. Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation. Scand J Gastroenterol 2008; 43: 1483-8.
8. Rao AS, Wong B, Camilleri M, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology 2010; 139: 1549-58.
9. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010; 8: 159-65.
10. Bajor A, Gillberg P-G, Abrahamsson H. Bile acids: short and long term effects in the intestine. Scand J Gastroenterol 2010; 45: 645-64.
11. Kirwan WO, Smith AN, Mitchell WD, et al. Bile acids and colonic motility in the rabbit and the human. Gut 1975; 16: 894-902.
12. Conley DR, Coyne MJ, Bonorris GG, et al. Bile acid stimulation of colonic adenylate cyclase and secretion in the rabbit. Am J Dig Dis 1976; 21: 453-8.
13. Chadwick VS, Gaginella TS, Carlson GL, et al. Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. J Lab Clin Med 1979; 94: 661-74. (Pubitemid 10210498)
14. Alrefai WA, Saksena S, Tyagi S, et al. Taurodeoxycholate modulates apical Cl-/OH-exchange activity in Caco2 cells. Dig Dis Sci 2007; 52: 1270-8. (Pubitemid 46626156)
15. Gillberg PG, Dahlström M, Starke I, et al. The IBAT inhibition by A3309-a potential mechanism for the treatment of constipation. Gastroenterology 2010; 5 (Suppl 1): 224.
16. Simren M, Abrahamsson H, Bajor A, et al. The IBAT inhibitor A3309-a promising treatment option for patients with chronic idiopathic constipation . Gastroenterology 2010; 5 (Suppl 1): 223.
17. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders . Gastroenterology 2006; 130: 1480-91.
18. O' Donell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. Br Med J 1990; 300: 439-40. (Pubitemid 20069266)
19. Rex D, Johnson DA, Anderson JC, et al. American college of gastroenterology guidelines for colorectal cancer screening 2008. Am J Gastroenterol 2009; 104: 739-50.
20. Food and Drug Administration [Internet]. Guidance for Industry: Irritable Bowel Syndrome-Clinical Evaluation of Products for Treatment [updated 4 March 2010; cited 27 January 2011]. Available at: http://www. fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM205269.pdf.
21. Gälman C, Angelin B, Rudling M. Bile acid synthesis in humans has a rapid diurnal variation that is asynchronous with cholesterol synthesis. Gastroenterology 2005; 129: 1445-53. (Pubitemid 41597387)
22. Angelin B, Eriksson M, Rudling M. Bile acids and lipoprotein metabolism: a renaissance for bile acids in the post-statin era? Curr Opin Lipidol 1999; 10: 269-74. (Pubitemid 29405917)
23. Bertolotti M, Zambianchi L, Carulli L, et al. Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption. Hepatology 2003; 38: 939-46. (Pubitemid 37221677)
24. Naoumova RP, O' Neill FH, Dunn S, et al. Effect of inhibiting HMG-CoA reductase on 7 α-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. Eur J Clin Invest 1999; 29: 404-12. (Pubitemid 29211862)
25. Edwards CA, Brown S, Baxter AJ, et al. Effect of bile acids on anorectal function in man. Gut 1989; 30: 383-6. (Pubitemid 19091167)
26. Bampton PA, Dinning PG, Kennedy ML, et al. The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol Gastrointest Liver Physiol 2002; 282: G443-9. (Pubitemid 34651659)
27. Mitchell WD, Findlay JM, Prescott RJ, et al. Bile acids in the diarrhoea of ileal resection. Gut 1973; 14: 348-53.
28. Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004; 2: 796-805. (Pubitemid 39200718)
29. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010; 138: 886-95.
30. Locke GR III, Pemberton JH, Phillips SF. American gastroenterological association medical position statement: guidelines on constipation . Gastroenterology 2000; 119: 1761-6. (Pubitemid 32198702)
31. Spiller RC, Thompson WG. Bowel disorders. Am J Gastroenterol 2010; 105: 775-85.